rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
1986-5-1
|
pubmed:abstractText |
Serum concentrations of the CA 19-9 antigen were determined in 91 patients with pancreatic cancer and in 111 patients with benign pancreatic, biliary and hepatocellular diseases. The CA 19-9 concentration was above the cut-off limit (37 U ml-1) in 78% of the patients with pancreatic cancer and high levels (greater than 500 U ml-1) were seen in 56% of these patients. Elevated levels were also seen in benign diseases (22%), especially in patients with extrahepatic cholestasis (up to 440 U ml-1). Hepatocellular jaundice and pancreatitis were associated with normal values (84% of the patients), or with only slightly elevated CA 19-9 levels (up to 88 U ml-1). The CA 19-9 test can be useful as an additional diagnostic tool for the detection of pancreatic cancer. Preliminary results suggest that the CA 19-9 assay can be used in the monitoring of surgically treated patients.
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-3513813,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-354771,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-6163212,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-6193872,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-6198342,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-6199316,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-6582896,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-6825270,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-7068815,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-7142214,
http://linkedlifedata.com/resource/pubmed/commentcorrection/3456787-94699
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0007-0920
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
53
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
197-202
|
pubmed:dateRevised |
2009-11-18
|
pubmed:meshHeading |
pubmed-meshheading:3456787-Alkaline Phosphatase,
pubmed-meshheading:3456787-Antigens, Neoplasm,
pubmed-meshheading:3456787-Antigens, Tumor-Associated, Carbohydrate,
pubmed-meshheading:3456787-Biliary Tract Diseases,
pubmed-meshheading:3456787-Bilirubin,
pubmed-meshheading:3456787-Carcinoembryonic Antigen,
pubmed-meshheading:3456787-Humans,
pubmed-meshheading:3456787-Jaundice,
pubmed-meshheading:3456787-Pancreatic Neoplasms,
pubmed-meshheading:3456787-Pancreatitis,
pubmed-meshheading:3456787-Time Factors
|
pubmed:year |
1986
|
pubmed:articleTitle |
Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|